Suzanne Lentzsch, MD, PhD, Columbia University

Expert perspective on the INSURE study, which pooled data from several trials to observe the real-world effectiveness of IRd in the setting of relapsed/refractory multiple myeloma.

Suzanne Lentzsch, MD, discusses how patient age informs treatment decisions in multiple myeloma.

Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.

Novel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.

Current unmet needs surrounding the management of patients with triple-class refractory multiple myeloma with newer novel therapies.

Guidance regarding proper treatment selection and sequencing of therapies for triple-class refractory multiple myeloma.

An overview of the DREAMM-2 study of belantamab mafodotin for triple-class refractory patients with multiple myeloma, with special considerations for managing treatment-related corneal events.

The rationale for adding melflufen to dexamethasone as treatment for patients with triple-class refractory multiple myeloma.

Considerations for adding selinexor to backbone treatments for triple-class refractory multiple myeloma based on data revealed by the STOMP trial.

Insight regarding the risk of development of triple-class refractory disease in multiple myeloma and recommendations for working with patients to establish an appropriate treatment plan and counsel on goals of therapy.

Strategies for patient assessment and treatment selection in patients with relapsed/refractory multiple myeloma.

Criteria for diagnosis and risk stratification in patients with relapsed/refractory multiple myeloma.